Comparison of progression and non-progression in injecting drug users and homosexual men with documented dates of HIV-1 seroconversion

AIDS

Volumn 11, Issue 5, 1997, Pages 621-631

  Prins, Maria ^a   Veugelers, Paul J ^a  

^a MUNICIPAL HEALTH SERVICE   (Netherlands)

Author keywords

HIV seroconversion; Homosexual men; Injecting drug users; Non progression; Progression

Indexed keywords

CD4 ANTIGEN;

ADULT; ARTICLE; FEMALE; HIGH RISK POPULATION; HOMOSEXUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; SEROCONVERSION; SURVIVAL;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; FEMALE; HIV SEROPOSITIVITY; HOMOSEXUALITY, MALE; HUMANS; MALE; PROGNOSIS; RISK FACTORS; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 8044257705     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199705000-00010     Document Type: Article

References (51)

1. Brookmeyer R, Gail MH, Polk BF: The prevalent cohort study and the acquired immunodeficiency syndrome. Am J Epidemiol 1987, 126:14-24.
2. Spijkerman IJB, Langendam MW, Veugelers PJ, et al.: Differences in progression to AIDS between injection drug users and homosexual men with documented dates of seroconversion. Epidemiology 1996, 7:571-577.
3. Pezzotti P, Rezza G, Lazzarin A, et al.: Influence of gender, age and transmission category on the progression from HIV seroconversion to AIDS. J Acquir Immune Defic Syndr 1992, 5:745-747.
4. Biggar RJ, the International Registry of Seroconverters: AIDS incubation in 1891 HIV seroconverters from different exposure groups. AIDS 1990, 4:1059-1066.
5. Mariotto AB, Mariotti S, Pezzotti P, Rezza G, Verdecchia A: Estimation of the acquired immunodeficiency syndrome incubation period in intravenous drug users: a comparison with male homosexuals. Am J Epidemiol 1992, 135:428-437.
6. Gauvreau K, DeGruttola V, Pagano M, Bellocco R: The effect of covariates on the induction time of AIDS using improved imputation of exact seroconversion times. Stat Med 1994, 13:2021-2030.
7. Multicohort Analysis Project Workshop: Extending public health surveillance of HIV infection: information from a five cohort workshop. Stat Med 1993, 12:2065-2085.
8. Galai N, Vlahov D, Margolick JB, Chen K, Graham NMH, Muñoz A: Changes in markers of disease progression in HIV-1 seroconverters: a comparison between cohorts of injecting drug users and homosexual men. J Acquir Immune Defic Syndr Hum Retrovirol 1995, 8:66-74.
9. Multicohort nalysis Project Workshop: Immunologic markers of AIDS progression: consistency across five HIV-infected cohorts. Part I. AIDS 1994, 8:911-921.
10. Keet JPM, Krol A, Klein MR, et al.: Characteristics of long-term asymptomatic infection with human immunodeficiency virus type 1 in men with normal and low CD4+ cell counts. J Infect Dis 1994, 169:1236-1243.
11. Sheppard HW, Lang W, Asher MS, Vittinghoff L, Winkelstein W: The characterisation of non-progressors: long-term HIV-1 infection with stable CD4+ T-cell levels. AIDS 1993, 7:1159-1166.
12. Muñoz A, Kirby AI, He YD, et al.: Long-term survivors with HIV-1 infection: incubation period and longitudinal patterns of CD4+ lymphocytes. J Acquir Immune DeficSyndr 1995, 8:496-505.
13. Buchbinder SP, Katz MH, Hessol NA, O'Malley PM, Holmberg SD: Long-term HIV-1 infection without immunologic progression. AIDS 1994, 8:1123-1128.
14. Strathdee SA, Craib KJP, Hogg RS, O'Shaughnessy MVO, Montaner JSG, Schechter MI: Long-term non-progression in HIV infection (letter). Lancet 1995, 346:1372.
15. Phillips AN, Sabin CA, Elford J, Botill M Janossy G, Lee CA: Use of CD4 lymphocyte count to predict long term survival free of AIDS after HIV infection. Br Med J 1994, 309:313.
16. Stathdee SA, Veugelers PJ, Page-Shater KA, et al.: Lack of consistency between five definitions of nonprogression in cohorts of HIV-infected seroconverters. AIDS 1996, 10:959-965.
17. Brettle RP, McNeil AI, Burns S, et al.: Progression of HIV: follow-up of Edinburgh injecting drug users with narrow seroconversion intervals in 1983-1985. AIDS 1996, 10:419-430.
18. Skidmore CA Rebertson JR, Robertson AA, Elton RA: After the epidemic: follow up study of HIV seroprevalence and changing patterns of drug use. Br Med J 1990, 300:219-223.
19. Brettle RP, Bisset K, Burns S, et al.: Human immunodeficiency virus and drug misuse: the Edinburgh experience. Br Med J 1987, 295:421-424.
20. van den Hoek JAR, Coutinho RA van Haastrecht HJA, van Zadelhoff AW, Goudsmit I: Prevalence and risk factors of HIV infections among drug users and drug-using prostitutes in Amsterdam. AIDS 1988, 255-60.
21. Ledergerber B, Von Overbeck J, Egget M, Luthy R: The Swiss HIV Cohort Study: rationale, organization and selected baseline characteristics, ssoz Praventivmed 1994, 39:387-394.
22. Cané N, Deveu C, Belanger E, et al.: Effect of age and exposure group on the onset of AIDS in heterosexual and homosexual HIV-infected patients. AIDS 1994, 8:797-802.
23. Goldberg DJ, Emslie JA, Smyth W, Reid D. collaborating microbiologists: A system for surveillance of voluntary HIV testing: results of the first 2 years 1989-1990. AIDS 1992, 6:495-500.
24. Zangerle R, Luchs D, Rosster H, et al.: Trends in HIV infection among intravenous drug users in Innsbruck, Austria. J Acquir Immune Defic Syndr 1992, 5:865-87.
25. Veugelers PJ, Page KA, Lindall B, et al.: Determinants of HIV disease progression among homosexual men registered in the Tricontinental Seroconverter Study. Am J Epidemiol 1994, 140:747-758.
26. Centers for Diseases Control. Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. MMWR 1987, 6:1S-15S.
27. Veugelers PJ, Strathdee SA, Moss AR, et al.: Is the human immunodeficiency virus-related Kaposi's sarcoma epidemic coming to an end? Insights from the Tricontinental Seroconverter Study. Epideniology 1995, 6:382-386.
28. Law CG, Brookmeyer R: Effects of mid-point imputation on the analysis of doubly censored data. Stat Med 1992, 11 1569-1578.
29. Jongblood G: The Iterative Convey Minorant Algorithm for Nonparametric Estimation. Technical Report. Delft: Delft University of Technology, 1995
30. Groeneboom P, Wellner JA: Information Bounds and Non parametric Maximum Likelihood Estimatio. Berlin: Birkhauser Verlag, 1992.
31. van Haastrecht HJA van den Hock JAR, Coutinho RA: High mortality among HIV-infecled injecting drug users without AIDS-diagnosis: implications for HIV infection epidemic modellers? AIDS 1994, 8:363-366.
32. Lang W, Perkins H, Anderson R, et al.: Patterns of T-lymphocyte changes with human immunodeficiency virus infection: from seroconversion to the development of AIDS. J Acquir Immune Defic Syndr 1989, 2:63-69.
33. Margolick JB, Donnenberg AD, Muñoz A, et al.: Changes in T and non-T lymphocyte subsets following seroconversion to HIV-1: stable CD3+ and declining CD3-populations suggest regulatory responses linked to loss of CD4 lymphocytes. J Acquir Immune Defic Syndr 1993, 6:153-161.
34. Beral V, Peterman IA, Berkelman RL, Jaffe HW: Kaposi's sarcoma among persons with AIDS: a sexually transmitted infection? Lancet 1990, 335:123-128.
35. Crowe SM, Carlin JB, Stewart KJ, Lucas R, Hoy JF: Predictive value of CD4-lymphocyte numbers for the development of opportunistic infections and malignancies in HIV-infected persons. J Acquir Immune Defic Syndr 1991, 4:770-776.
36. Operskalski LA, Stram DO, Lee H, Transfusion Safety Study Group: Human immunodeficiency virus type 1 infection: relationship of risk group and age to rate of progression to AIDS. J Infect Dis 1995, 172:648-655.
37. Centers for Disease Control and Prevention: Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR 1992, 41 (RR-17):1-19.
38. Mientjes GHC, van Ameijden HC, Keet IPM, van Deutekom H, van den Hoek JAR, Coutinho RA: Disproportional impact of the revised AIDS surveillance definition on the AIDS incidence among drug users compared to homosexual men. Eur J Publ Health 1995, 6:288-290.
39. Dupon M, Jevier-Maugein J, Jeroy V, et al.: Tuberculosis and HIV infection: a cohort study of incidence and susceptibility to antituberculous drugs, Bordeaux, 1985-1993. AIDS 1995, 9:577-583.
40. Hirschtick RE, Glassroth J, Jordan MC, et al.: Bacterial pneumonia in persons infected with the human immunodeficiency virus. N Engl J Med 1995, 333:845-851.
41. Ronald PJM, Robertson JR, Elton RA: Continued drug use and other cofactors for progression to AIDS among injecting drug users. AIDS 1994, 8:339-343.
42. Rosenberg PS, Goedert H, Biggat RJ. Multicenter Hemophilia Cohort Study and the international Registry of Seroconverters: Effect of age at seroconverion on the natural AIDS incubation distribution. AIDS 1994 8:803-810.
43. The Italian Seroconversion Study Disease progression and early predictors of AIDS in HIV-seroconverted injecting drug users. AIDS 1992, 6:421-426.
44. Hessol NA, Koblin BA van Guensvetit GJP et al.. Progression of human immunodeficiency virus type 1 (HIV-1) infection among homosexual men in hepatitis B vaccine trial cohorts in Amsterdam, New York City, and San Francisco, 1978-1991. Am J Epidemiol 1994, 139:1077-1087.
45. Darby SC, Iwatt DW, Giangrande PH, Spooner RJD, Rizza CR, the UK Heamophilia Centre Directions' Organization: Importance of age at infection with HIV-1 for survival and development of AIDS in UK haemophilia population. Lancet 1996, 347:1573-1579.
46. Martin JN, Colford JM, Ngo I Lager IB: Effect of older age on survival in human immunodeficiency virus (HIV) disease. Am J Epidemiol 1995, 142:1221-1230.
47. Selwyn PA, Alcabes P, Hartel D, et al.: Clinical manifestations and predictors of disease progression in drug users with human immunodeficiency virus infection. N Engl J Med 1992, 327:1697-1703
48. Goedert JJ, Pizza G, Graffi JM, et al.: Mortality among drug users in the AIDS era. Int J Epidemiol 1995, 24:1204-1210.
49. Zaccarelli M, Gattan P, Rezza G, et al.: Impact of HIV infection on non-AIDS mortality among Italian injecting drug users. AIDS 1994, 8:345-350.
50. Stoneburner RL, Des Jarlais DC, et al.: A larger spectrum of severe HIV-1 related disease in intravenous drug users in New York City. Science 1988, 242:916-919.
51. van Haastrecht HJA, van American HJC, van den Hock JAR, Mientjes GHC, Bax JS, Coutinho RA: Predictors of mortality in the Amsterdam cohort of HIV-positive and HIV-negative drug users. Am J Epidemiol 1996, 143:380-391.